item 2, case 2014, 0243, 3927 through 3931 19th street. indefinite continuance. under the regular calendar, staff is requesting that item 17 for case number 2015, 00419, 333 12th street, conditional use authorization, to be continued to february 13, 2020. no other items for continuance and no speaker cards. president koppel: any members of the public that would like to comment on the items proposed for continuance? come on up am come on up. hi, my name is tracy thompson. am i to understand we can comment on number one in the regular calendar right now? only to the matter of continuance, not the project itself. so i m confused. well, item 1 no, item 1, under the regular calendar. no we re just taking matters proposed for continuance. when do we speak for when that item is called. thanks, sorry. president koppel: any other members of the public wish to comment on items proposed for continuance, come on up. hello, i want to confirm there is 333 12th
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor. | May 12, 2023
Impel NeuroPharma Inc (IMPL) Appoints Darren Cline to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing therapies for rare and intractable forms of genetic
PARAMUS, N.J. - July 21, 2022 - (Newswire.com) Epygenix Therapeutics, a clinical-stage biopharmaceutical company powered by a novel genetic screening platform focused on developing treatm.